node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
CKLF | IL17B | ENSP00000264001 | ENSP00000261796 | Chemokine-like factor; May play an important role in inflammation and regeneration of skeletal muscle. Partly inhibited by interleukin 10 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | 0.513 |
CXCL1 | IL17B | ENSP00000379110 | ENSP00000261796 | Growth-regulated alpha protein; Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO- alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity; Chemokine ligands | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | 0.476 |
CXCL1 | IL17RA | ENSP00000379110 | ENSP00000320936 | Growth-regulated alpha protein; Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO- alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity; Chemokine ligands | Interleukin-17 receptor A; Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Receptor for IL17C as part of a heterodimeric complex with IL17RE. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6; CD molecules | 0.664 |
CXCL1 | IL17RC | ENSP00000379110 | ENSP00000295981 | Growth-regulated alpha protein; Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO- alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity; Chemokine ligands | Interleukin-17 receptor C; Isoform 8- Receptor for both IL17A and IL17F; Interleukin receptors | 0.571 |
CXCL1 | IL25 | ENSP00000379110 | ENSP00000328111 | Growth-regulated alpha protein; Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO- alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity; Chemokine ligands | Interleukin-25; Induces activation of NF-kappa-B and stimulates production of the proinflammatory chemokine IL-8. Proinflammatory cytokine favoring Th2-type immune responses; Belongs to the IL-17 family | 0.473 |
IL17B | CKLF | ENSP00000261796 | ENSP00000264001 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Chemokine-like factor; May play an important role in inflammation and regeneration of skeletal muscle. Partly inhibited by interleukin 10 | 0.513 |
IL17B | CXCL1 | ENSP00000261796 | ENSP00000379110 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Growth-regulated alpha protein; Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO- alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity; Chemokine ligands | 0.476 |
IL17B | IL17RA | ENSP00000261796 | ENSP00000320936 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-17 receptor A; Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Receptor for IL17C as part of a heterodimeric complex with IL17RE. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6; CD molecules | 0.951 |
IL17B | IL17RB | ENSP00000261796 | ENSP00000288167 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-17 receptor B; Receptor for the proinflammatory cytokines IL17B and IL17E. May play a role in controlling the growth and/or differentiation of hematopoietic cells; Interleukin receptors | 0.984 |
IL17B | IL17RC | ENSP00000261796 | ENSP00000295981 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-17 receptor C; Isoform 8- Receptor for both IL17A and IL17F; Interleukin receptors | 0.770 |
IL17B | IL17RD | ENSP00000261796 | ENSP00000296318 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-17 receptor D; Feedback inhibitor of fibroblast growth factor mediated Ras-MAPK signaling and ERK activation. May inhibit FGF-induced FGFR1 tyrosine phosphorylation. Regulates the nuclear ERK signaling pathway by spatially blocking nuclear translocation of activated ERK without inhibiting cytoplasmic phosphorylation of ERK. Mediates JNK activation and may be involved in apoptosis. Might have a role in the early stages of fate specification of GnRH-secreting neurons (By similarity); Interleukin receptors | 0.689 |
IL17B | IL17RE | ENSP00000261796 | ENSP00000373325 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-17 receptor E; Specific functional receptor for IL17C. May be signaling through the NF-kappa-B and MAPK pathways. May require TRAF3IP2 /ACT1 for signaling. May be a crucial regulator in innate immunity to bacterial pathogens. Isoform 2 and isoform 4 may be either cytoplasmic inactive or dominant active forms. Isoform 3 and isoform 5 may act as soluble decoy receptors | 0.806 |
IL17B | IL24 | ENSP00000261796 | ENSP00000375795 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-24; Has antiproliferative properties on melanoma cells and may contribute to terminal cell differentiation; Belongs to the IL-10 family | 0.477 |
IL17B | IL25 | ENSP00000261796 | ENSP00000328111 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-25; Induces activation of NF-kappa-B and stimulates production of the proinflammatory chemokine IL-8. Proinflammatory cytokine favoring Th2-type immune responses; Belongs to the IL-17 family | 0.870 |
IL17B | IL26 | ENSP00000261796 | ENSP00000229134 | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | Interleukin-26; May play a role in local mechanisms of mucosal immunity and seems to have a proinflammatory function. May play a role in inflammatory bowel disease. Activates STAT1 and STAT3, MAPK1/3 (ERK1/2), JUN and AKT. Induces expression of SOCS3, TNF-alpha and IL-8, secretion of IL-8 and IL-10 and surface expression of ICAM1. Decreases proliferation of intestinal epithelial cells. Is inhibited by heparin; Interleukins | 0.501 |
IL17RA | CXCL1 | ENSP00000320936 | ENSP00000379110 | Interleukin-17 receptor A; Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Receptor for IL17C as part of a heterodimeric complex with IL17RE. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6; CD molecules | Growth-regulated alpha protein; Has chemotactic activity for neutrophils. May play a role in inflammation and exerts its effects on endothelial cells in an autocrine fashion. In vitro, the processed forms GRO- alpha(4-73), GRO-alpha(5-73) and GRO-alpha(6-73) show a 30-fold higher chemotactic activity; Chemokine ligands | 0.664 |
IL17RA | IL17B | ENSP00000320936 | ENSP00000261796 | Interleukin-17 receptor A; Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Receptor for IL17C as part of a heterodimeric complex with IL17RE. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6; CD molecules | Interleukin-17B; Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1; Interleukins | 0.951 |
IL17RA | IL17RB | ENSP00000320936 | ENSP00000288167 | Interleukin-17 receptor A; Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Receptor for IL17C as part of a heterodimeric complex with IL17RE. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6; CD molecules | Interleukin-17 receptor B; Receptor for the proinflammatory cytokines IL17B and IL17E. May play a role in controlling the growth and/or differentiation of hematopoietic cells; Interleukin receptors | 0.928 |
IL17RA | IL17RC | ENSP00000320936 | ENSP00000295981 | Interleukin-17 receptor A; Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Receptor for IL17C as part of a heterodimeric complex with IL17RE. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6; CD molecules | Interleukin-17 receptor C; Isoform 8- Receptor for both IL17A and IL17F; Interleukin receptors | 0.947 |
IL17RA | IL17RE | ENSP00000320936 | ENSP00000373325 | Interleukin-17 receptor A; Receptor for IL17A. Receptor for IL17F. Binds to IL17A with higher affinity than to IL17F. Binds IL17A and IL17F homodimers as part of a heterodimeric complex with IL17RC. Also binds heterodimers formed by IL17A and IL17F as part of a heterodimeric complex with IL17RC. Receptor for IL17C as part of a heterodimeric complex with IL17RE. Activation of IL17RA leads to induction of expression of inflammatory chemokines and cytokines such as CXCL1, CXCL8/IL8 and IL6; CD molecules | Interleukin-17 receptor E; Specific functional receptor for IL17C. May be signaling through the NF-kappa-B and MAPK pathways. May require TRAF3IP2 /ACT1 for signaling. May be a crucial regulator in innate immunity to bacterial pathogens. Isoform 2 and isoform 4 may be either cytoplasmic inactive or dominant active forms. Isoform 3 and isoform 5 may act as soluble decoy receptors | 0.989 |